FDA Approved: EXFORGE HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA supplemental application for EXFORGE HCT, a fixed-dose combination of amlodipine, valsartan, and hydrochlorothiazide, submitted by Novartis, seeking changes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Exforge HCT (amlodipine/valsartan/hydrochlorothiazide)

Snippet

SUPPL AP for EXFORGE HCT (AMLODIPINE VALSARTAN AND HYDROCHLOROTHIAZIDE)